

PTO/SB/96 (09-04)

Approved for use through 07/31/2008, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: M. Rigdon LentzApplication No./Patent No.: 09/316,226 / 6,231,536 Filed/Issue Date: May 21, 1999 / May 15, 2001Entitled: Method and Compositions for Treatments of CancersBiopheresis Technologies, LLC a limited liability corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012991, Frame 0166, or for which a copy thereof is attached.
- OR
- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Rivka D. Monheit October 4, 2004
Signature Date
Rivka D. Monheit, Reg. No. 48,731 404-679-2152
Printed or Typed Name Telephone Number
Attorney of Record
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

LEN 101 CIP - 077829/00008

PTO/SB/96 (09-04)

Approved for use through 07/31/2006, OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: M. Rigdon LentzApplication No./Patent No.: 09/669,003 Filed/Issue Date: October 28, 2000Entitled: **METHOD AND COMPOSITIONS FOR TREATMENTS OF CANCERS**Biophoresis Technologies, LLCa limited liability corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012991, Frame 0166, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Rivka D. MonheitOctober 4, 2004

Signature

Date

Rivka D. Monheit, Reg. No 48,731404-879-2152

Printed or Typed Name

Telephone Number

Attorney of Record

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/96 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: M. Rigdon LentzApplication No./Patent No.: 09/709, 045 Filed/Issue Date: November 10, 2000Entitled: **METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS**Biopheresis Technologies, LLC a limited liability corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012991, Frame 0166, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Rivka D. Monheit

Signature

October 4, 2004

Date

Rivka D. Monheit, Reg. No. 48,731

Printed or Typed Name

404-879-2152

Telephone Number

Attorney of Record

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction

Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08 (08-06)

Approved by the Office of Management and Budget through 10/31/2002; OMB 0551-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: M. Rigdon LentzApplication No./Patent No.: 09/083,307 / 6,620,382 File/Issue Date: May 22, 1998Entitled: Method and Compositions for Treatment of CancersBiophoresis Technologies, LLC, a limited liability corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is: _____ %
in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012991 Frame 0165, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee, as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____ or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____ or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____ or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08].

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

July 16, 2003

Date

Jeffrey S. Mair

Typed or printed name

Signature

Member of the Board of Managers

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on this amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

LSN 301-07728/00003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

OCT 04 2004

Applicants: M. Rigdon Lentz

Serial No.: 09/699,003

Art Unit: 3762

Filed: October 26, 2000

Examiner: P. Bianco

For: *METHODS AND COMPOSITIONS FOR TREATMENT OF CANCERS*Assistant Commissioner for Patents
Washington, D.C. 20231

Declaration under 37 C.F.R. 1.131

Sir:

I, M. Rigdon Lentz,

1. I am the inventor of the above-identified application.
2. I conceived of the method of using an immobilized antibody column to remove soluble cytokine receptors to induce an inflammatory response and tumor remission in patients, and system for use therein, and conveyed this information to my patent attorney, Patrea Pabst, prior to May 1998, when Selinsky, et al., "Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I" Immunology 94, 88-93 (1998), was published. This is demonstrated by attachment A, the marked up draft of the patent application which I returned to Patrea Pabst with my comments on April 20, 1998.
3. I then diligently proceeded to reduce this method to practice by filing a patent application U.S.S.N. 09/083,307 on May 22, 1998. It is not clear on what date Selinsky

U.S.S.N. 09/699,003
Filed October 26, 2000
Declaration Under 37 C.F.R. 1.131

was published. Based on the comments by Examiner Lorraine Spector in U.S.S.N. 09/709,045, Selinsky was not published until after my patent application was filed, since the publication was not received by the US Patent Office until May 28, 2004. To the extent it was published before I filed my patent application, I have provided additional evidence that I acted diligently from the date of its publication in filing my patent application. This is demonstrated in part by Attachment B is copy of a letter dated May 2, 1998 regarding further correspondence about changes to the draft application Attachment B, and providing additional data to incorporate into the application.

4. I declare that all statements made herein of my own knowledge and belief are true and that all statements made on information and belief are believed to be true, and further, that the statements are made with the knowledge that willful false statements are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

M. Rigdon Lentz

LENTZ APHERESIS CENTER

397 WALLACE RD. SUITE 314

NASHVILLE, TN 37211

FAX: (615)-834-8004

PH: (615)-831-1222

Attachment
A**FACSIMILE TRANSMITTAL FORM****PLEASE DELIVER IMMEDIATELY AS THIS INFORMATION IS REGARDED URGENT**

DATE: 4-20-98

TIME: 1:30 pm

DELIVER TO: Pulera Pulera c.c. Jeff Munn

FACSIMILE #: (404)-843-8495

FROM: Dr. Lentz

PAGES INCLUDING THIS ONE: 21

MESSAGE:

NOTE: THIS FACSIMILE CONTAINS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE SPECIFIC INDIVIDUAL OR ENTITY NAMED ABOVE. IF YOU OR YOUR REPRESENTATIVE ARE NOT THE INTENDED RECIPIENT, YOU ARE HERBY NOTIFIED THAT ANY UNAUTHORIZED DISSEMINATION OR COPYING OF THIS FACSIMILE OR THE INFORMATION CONTAINED HEREIN IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE ABOVE AND RETURN ORIGINAL FAX TO US AT ABOVE ADDRESS VIA THE US POSTAL SERVICE. THANK YOU.



M. Rigdon Lentz, M.D.
397 Wallace Road, Suite 314
Nashville, TN 37211

11653/3

to: Patrea Pabst
Arnall Golden & Gregory, LLP
2800 one Atlantic Center
1201 West Peachtree street
Atlanta, Georgia 30309-3450

subj: Patent - Method and Compositions for Treatment of Cancers

Dear Mrs Pabst:

Thank you for your thorough work and excellent job in preparing this application. I have reviewed it as you requested and have offered some few remarks of a technical nature and have tried to add the additional information where indicated. These additions are as follows:

1. pg.1, line.19. after GM-CSF, "erythropoietin, thrombopoietin, G-CSF, M-CSF and SCF."
2. pg.2, line.27 after ultrafilter "or parallel plate filter" line.29 after filter "at least"
3. pg 3, line. 6 after IL-2, "IFNs". line. 7 after increases "the inflammation against tumors by allowing cytokines, such as TNF to work effectively."
4. pg. 3, line. 10 after taxol" and other drugs which may be synergistic in effect with "unblocked" cytokines." line. 19. after receptors "or inhibitors to IL-2, IL-6, gamma interferon, or other pro-inflammatory signaling as well as white cell activation."
5. pg. 3 line.27 after polypropylene"ethylene polyvinyl alcohol or polysulfone"
6. pg. 4 line.9 add sentence after components "Specific absorbing columns can also be employed to selectively remove specific cytokine and cellular inhibitors from the filtered plasma so that the so treated ultrafiltrate of plasma maybe returned to the patient to achieve the desired effect."
7. pg. 4 line 30 Kuraray Co., Ltd
1-12-39, Umeda, Kita-ku,
Osaka 530 Japan

Phone (615) 831-1222

Fax (615) 834-8004



M. Rigdon Lentz, M.D.
397 Wallaco Road, Suite 314
Nashville, TN 37211

8. pg. 5, line10 change "weight" to "volume". line13 change "a compatible plasma" to "normal saline"
9. pg.7, line 25 after size "or which suggests tumor inflammation. "
line. 27 after tumors "and/or inflammation".
10. pg.8 line. 10 "glioblastomas" line15 "TNF alpha and beta receptors"
11. pg.9 line 23 **Cytokines** The biologic activity and clinical effectiveness of pro-inflammatory cytokines is augmented in the patient with cancer and other states of acquired immune tolerance by ultrapheresis. Specifically TNF both alpha and TNF beta, in doses 100 to 500 micgms per meter squared body surface area (M2 BSA). Monocyte and lymphocyte activation by INFs -alpha, beta and gamma is augmented. The IL-1 and IL-2 receptor antagonists are removed by this form of ultrapheresis thereby upregulating the in vivo activity of these cytokines. An 80kd glycoprotein has been recently found, full description pending, which is responsible for inhibiting blastoid transformation in advanced malignancy, chronic infectious disease and pregnancy and appears to be responsible for the loss of delayed hypersensitivity reactions in these diseases and it too is remove by this process. This is significant because in removing this type of suppression, vaccines of all types will work better. Dosage regimes for IFN - $\alpha\beta$ 3 M units sq three times a week up to 20m units /M2 BSA daily. IFN- γ 100 to 1000 micgms per day.
TNF
pg. 9, line28 change "TNA-alpha" to "TNF R-1&R-2 receptor/inhibitor molecules"
11. pg.10, line.14 Tamoxifen plays a role in not only blocking of estrogen receptors but also certain growth factor receptors such as EDGF,FDGF, TDGF-B,and PDGF and therefore may be complimentary to inflammation against cancers provoked by ultrapheresis.
12. pg. 10 line.15 **Radiation** Because radiation therapy is so destructive of normal tissue, causing tumors to die partially by an inflammatory attack allows the use of lower doses of radiation to kill residual tumor cells and spare normal tissue. It is anticipated that by using this form of immunotherapy as initial therapy, that subsequent effective doses of radiation could be reduced in half. It is also well established that TNF kills tumor cells by generating free oxygen radicals, hydroxal radicals and halide ions, radiation therapy generates carbonium ions in tissue and the combination of the two is more effective in kill cancer cells than either alone.
13. pg.12 line.15. change "TNF-alpha" to "TNF-R-1&R-2 receptors"

Phone (615) 831-1222

Fax (615) 834-8004



M. Rigdon Lentz, M.D.
397 Wallace Road, Suite 314
Nashville, TN 37211

I look forward to discussing these changes with you. I am certain that you will do far better than I at making all this clear. Thank you again for all your good work.

Sincerely


M. Rigdon Lentz

Phone (615) 831-1222

Fax (615) 834-8004

OCT. 4. 2004 8:20PM

PABST PATENT GROUP

LENTZAPHERESISCENTER

NO. 1732

P. 34

PAGE 02

RightFAX NT

4/1 18

PAGE 19/20 | RightFAX

APPLICATION

FOR

UNITED STATES LETTERS PATENT

BY

M. RIGDON LENTZ

FOR

METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS

537044

114374

540515

13

METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS

Abstract

A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxorubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

07/004

11033/1

1

METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS**Background of the Invention**

The present invention is generally in the field of enhancing an immune response, and particularly relates to the removal of inhibitors of immune mediators, in combination with anti-angiogenic compounds, cytokines, compounds inducing a procoagulant state, chemotherapeutic and/or radiation.

Conventional cancer therapy is based on the use of drugs and/or radiation which kills replicating cells, hopefully faster than the agents kill the patient's normal cells. Surgery is used to reduce tumor bulk, but has little impact once the cancer has metastasized. Radiation is effective only in a localized area.

The treatments can in themselves kill the patient, in the absence of maintenance therapy. For example, for some types of cancer, bone marrow transplants have been used to maintain the patient following treatment with otherwise fatal amounts of chemotherapy. Efficacy has not been proven for treatment of solid tumors, however. "Cocktails" of different chemotherapeutic agents and combinations of very high doses of chemotherapy with restorative agents, for example, GM-CSF, to restore platelet and white cell levels, are used to treat aggressive cancers.

Other treatments have been tried in an attempt to improve mortality and morbidity. Vaccines to stimulate the patient's immune system have been attempted, but not with great success. Various cytokines, alone or in combination, such as tumor necrosis factor, interferon gamma, and IL-2 have been used to kill cancers, but have not produced cures. More recently, anti-angiogenic compounds such as thalidomide have been tried in compassionate use cases and shown to cause tumor remission. In animal studies,

337086

116531

compounds inducing a procoagulant state, such as an inhibitor of protein C, have been used to cause tumor remission. New studies have shown that cytokine receptors, such as tumor necrosis factor receptors (TNF-Rs) are released in a soluble form from tumor cells, in high concentrations relative to normal cells, which may block the immune system's attack on the tumor cells (Jablonska and Peitruska, Arch. Immunol. Ther. Exp. (Warsz) 1997, 45(5-6), 449-453; Chen, et al., J. Neuropathol. Exp. Neurol. 1997, 56(5), 541-550).

U.S. Patent No. 4,708,713 to Lentz describes an alternative method for treating cancer, involving ultrapheresis to remove compounds based on molecular weight, which promotes an immune attack on the tumors by the patient's own white cells. Although results have been extremely promising, the treatment usually only produces remissions, not cures.

Despite all of these efforts, many patients die from cancer; others are terribly mutilated. It is unlikely that any one therapy will be effective to cure all types of cancer.

It is therefore an object of the present invention to provide a method and compositions for treatment of solid tumors.

It is a further object of the present invention to provide a method and compositions that does not involve non-selective, extremely toxic, systemic chemotherapy.

Summary of the Invention

A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter ^{or a small plastic filter} having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed

3

normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated.

The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases ^{the effectiveness of anti-tumor effect} endogenous, ~~local~~ cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxorubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

to work effectively.
which may be synergistic in effect with "radiation" therapy

Brief Description of the Drawings

Figures 1 and 2 are schematics of the system for ultrapheresis.

Detailed Description of the Invention

The methods and devices disclosed herein are useful for treatment of patients with cancer, immune-mediated disorders, chronic parasitism, some viral diseases, and other disorders characterized by elevated levels of TNF receptors. Examples demonstrate efficacy in treating cancer patients.

I. Ultrapheresis

A. Ultrapheresis System

1. Filters

The filter must be biocompatible, and suitable for contact with blood, without causing excessive activation of platelets or clotting. Such devices for use in kidney dialysis are well known. For use herein, the filter membranes, which will typically be a biocompatible or inert thermoplastic such as polycarbonate or polypropylene, having a pore size of between 0.02 and 0.05 microns. The actual pore size that yields the desired cutoff of approximately 120,000 daltons is determined based on the fluid flow geometry, shear

or inhibition of TNF, IL-6, gamma interferon and white cell activation
Exclusion of platelets & polypropylene

537046

116520

4

forces, flow rates, and surface area. The effective cutoff for a capillary membrane filter with a pore size of 0.03 microns is 120,000 daltons, with a sieving coefficient of between 10 and 30%. This results in only a trivial amount of IgG being removed from the patient's blood. The filter membrane should be less than about 25 microns, preferably less than about 10 microns, thick. Suitable materials for the ultrafilter membrane include sheets of polytetrafluoroethylene (Teflon R) and polycarbonate resins. The permeable membrane should not cause blood clotting or otherwise react with the blood.

Devices will typically be either parallel plate filters or capillary membrane filters. These can be adapted from devices currently in use for kidney dialysis. The capillary membrane filters will typically have a surface area of between about 0.25 and 1 m² for use with children and between about 1 and 3 m² for use with adults. The parallel plate filters will typically have a surface area in the range from 0.1 and 2 cm²/ml of blood to be filtered.

Staged filters can also be used, which have different pore sizes and/or geometries or surfaces areas, to provide for a "staggered" removal of materials from the blood. Alternatively, although not at this time preferred, one can use differential centrifugation, to provide for an appropriate separation of blood components.

A preferred membrane is one in which the pores are made by electron beams directed perpendicularly to the surface because the size and density of the pores can be accurately controlled in this manner. The pores are essentially circular in cross section so the effective pore size is the actual pore size. The effective pore size of ultrafiltered media having pores with non-circular cross sections shall be the diameter of a circular pore which will pass molecules or other components of an equivalent size to the molecules or other components which pass through the filter medium in question.

Suitable devices can be obtained from Asahi Chemical Company and Kuraray, Japan. (check names and provide addresses)

537080

KURARAY CO., LTD.
1-12-39, Jomoecho, Nishi-Ku,
Osaka 550 Japan.

11/03/1

5

2. Process Controls and Fluid Handling

The patient will typically be connected to the blood processing device using standard intravenous tubing, with connections similar to those used for platelepheresis, so that blood can be removed from the patient at one site and returned at another. The tubing is connected to a pump that controls the flow rate so that in the preferred embodiment one blood volume (based on approximately 7% of the total body weight) is processed over a period of approximately 2 1/2 hours. The filtrate is then returned from the filtration device to the patient at the second site. Standard microprocessor controls can be used to regulate the blood flow, for example, by monitoring the weight of the blood products being removed, in combination with flow rate monitors and pump speed.

The entire system should be first flushed with ^{saline} ~~a compatible plasma~~ and then treated with an anticoagulant or ant clotting agent, such as sodium heparin, to be sure that there are no locations within the system where blood clotting can occur. Moreover, small amounts of anticoagulants should be continuously introduced into the blood stream directed to the ultrafilter to ensure that no clotting occurs during the filtration process. All of the surfaces of the system which come in contact with the blood and fluids which are infused into the patient must be sterilized prior to commencing treatment.

Figure 1 illustrates a system for ultrapheresis. Blood is removed from a patient by means of a venous catheter 10 with the distal lead 11 thereof disposed in the superior vena cava 12 leading to the patient's heart 13. The blood passes through conduit 14 to a drip chamber 15 and then into pump 16 which controls the pressure of the blood to the separation unit 17, preferably an ultrafilter as shown, through conduit 18. A pressure gauge 19 is provided on conduit 14 to continually monitor arterial pressure. A syringe pump 20 feeds an anti-clotting drug such as sodium heparin to conduit 18 to prevent

the clotting of blood in the ultrafilter 17. In the ultrafilter 17 the blood stream passes over the ultrafilter medium or membrane 21 under pressure. The blood fraction including the low molecular weight components passes through the membrane 21 and is discharged as permeate through conduit 22. The retentate or treated blood containing the high molecular weight components, which include whole blood cells and platelets, is discharged into conduit 23 which ultimately leads back to the patient. Volumetric pump 27 passes a controlled amount of permeate to a container 28 for containment and for measuring. Volumetric pump 30, which is preferably the same type and capacity as pump 27, pumps replacement fluid from a container 31 to conduit 32, which mixes the fluid to conduit 23 where it mixes with the retentate or treated blood. The treated blood and other components are returned to the patient through venous catheter 34, the distal or discharge end of which is disposed in the brachiocephalic vein. The volumetric pumps 27 and 30 are preferably set either to pump the same total amount of fluid or to pump at the same rate, so that the same volume of fluid which is removed from the patient's blood stream as permeate is returned as replacement fluid. The blood stream in conduit 23 is passed through filter 36 to remove clots or other debris from the blood stream. A drip chamber 37 ensures that no significant quantities of air enter the patient's blood stream. A pressure gauge 38 is provided to continually monitor venous blood pressure.

Figure 2 illustrates another embodiment wherein blood removed from a patient is first passed through conduit 30 to a first ultrafilter 31 to selectively separate a blood fraction with components having molecular weights less than about 1,000,000 Daltons. The retentate from this ultrafilter 31 which contains the high molecular weight components is returned through conduit 32 to the patient. The permeate from the first ultrafilter 31 is passed through conduit 33 to a second ultrafilter 34 where a

7

blood fraction having a molecular weight below 30,000 is removed from the permeate stream from the first ultrafilter 30. The permeate from the second ultrafilter 34, which contains the very low molecular weight components such as salts and nutrients may be returned to the patient through conduit 38. The retentate from the second ultrafilter which contains circulating factors, ~~such~~ immunoglobulins and other components is discharged through conduit 36 and 13.

Blood should be pumped through the ultrafilter unit at sufficient pressure to cause the blood components having the immunosuppressive effects to pass through the filter but at a velocity which will not excessively shear or otherwise damage the blood cells passing over the membrane. Generally it has been found that the ratio of the area of the membrane to the amount of blood treated per hour should be within about 0.1 to 2 cm/mL. Differential pressure across the membrane should range from about 2 to 20 mm Hg.

3. Replacement Fluids

The patient must receive replacement fluids following filtration. The preferred replacement fluid is ~~ultrapheresis~~ normal plasma, for example, expired plasma obtained from the Red Cross, which has been filtered using the same filter as used to treat the patient. Alternatively, the patient can be administered normal albumin, or fresh frozen plasma diluted with saline.

II. Treatment with Adjuvant Therapies

Standard ultrapheresis is conducted over a period of time until a positive indication is observed. This is typically based on diagnostic tests which show that there has been some reduction in tumor size. The patient is preferably treated daily for three weeks. diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated.

which may require tumor resection

*and a
inflammation*

537285

1165371

Surgical (or vacuum) removal of necrotic material may be required prior to or during treatment to avoid toxicity associated with high tumor burden.

This procedure has been demonstrated to cause remission of solid tumors in approximately 50% of patients who have failed all other treatment modalities [EXPAND HERE - WHAT KINDS OF CANCERS, WHAT WAS TREATMENT REGIME, WHAT DO YOU MEAN WHEN YOU SAY TREATMENT SHOWED EFFICACY] Types of tumors that are particularly sensitive to the ultrapheresis include epithelial tumors, sarcomas, melanomas, and ^{glioma} glioblastomas.

However, it would clearly be advantageous to cause complete remissions. Based on the presumed mechanism that the process is removing immune inhibitors produced by the tumors, especially inhibitors of cytokines and other immune mediators, it is possible to treat the patients with adjuvant or combination therapies, that enhance the results achieved with the ultrapheresis. ^{TNF + IL-2} TNF-alpha receptors are thought to be particularly important immune inhibitors. Therefore, compounds which enhance TNF activity are particularly preferred. These include anti-angiogenic compounds, such as thalidomide, procoagulant compounds, cytokines and other immunostimulants. Standard chemotherapeutic agents and/or radiation can ^{also be used with the ultrapheresis}

A. Anti Angiogenic Compounds

Any anti-angiogenic compound can be used. Exemplary anti-angiogenic compounds include TNP-470, U. S. patent No. 5,290,807; Angiostatin, U.S. Patent No. 5,639,725; Endostatin, and Thalidomide. Thalidomide is administered once daily, 200 mg orally.

B. Procoagulant Compounds

Protein C is a vitamin K-dependent plasma protein zymogen to a serine protease. Upon activation it becomes a potent anticoagulant.

Activated protein C acts through the specific proteolysis of the procoagulant cofactors, factor VIIIa and factor Va. This activity requires the presence of another vitamin K-dependent protein, protein S, calcium and a phospholipid (presumably cellular) surface. As described in Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al., p. 263 (J.B. Lippincott, Philadelphia, PA 1987), protein C circulates in a two-chain form, with the larger, heavy chain bound to the smaller light chain through a single disulfide link. Protein C is activated to activated protein C (APC). Thrombin is capable of activating protein C by the specific cleavage of the Arg¹²-Leu¹³ bond in the heavy chain. *In vivo*, in the presence of physiological concentrations of calcium, the rate of this activation is enhanced dramatically when thrombin is bound to the endothelial cell cofactor, thrombomodulin. Matschiner, et al., Current Advances in Vitamin K Research, pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988) have further reviewed the role of the Vitamin K dependent proteins in coagulation.

Blockage of the natural anticoagulant pathways, in particular the protein C pathway, uses the natural procoagulant properties of the tumor to target the tumor capillaries for microvascular thrombosis, leading to hemorrhagic necrosis of the tumor, as described in U.S. Patent No. 5,147,638 to Ramon, et al. Examples of such compounds include anti-protein C and anti-protein S.

C. Cytokines

[PLEASE PROVIDE DISCUSSION REGARDING WHAT CYTOKINES MIGHT BE USEFUL, DOSAGES AND TREATMENT REGIMES]

D. Anti-TNA receptor molecules.

It is well established that TNF- α receptor molecules are shed by tumor cells, and that these molecules appear to inhibit immune mediated

10

attack by the host on the tumor cells. The ultrapheresis is believed to remove the majority of these soluble receptors. Additional, and/or selective, removal of these molecules can be obtained using antibody, or antibody fragments (single chain, recombinant, or humanized), immunoreactive against the receptor molecules. In the preferred embodiment, these antibodies are immobilized on the ultrapheresis membrane filters, using standard antibody coupling techniques. In the most preferred embodiment, the antibody is reactive with the carboxy-terminus of the shed receptor molecules, thereby avoid concerns with signal transduction by the receptor is still present on cell surface.

D. Chemotherapeutic Agents

Preferred chemotherapeutic agents are those which are synergistic with TNF, for example, alkylating agents, doxorubicin, carboplatinum, cisplatinum, and taxol/tamoxifen?

E. Radiation

DOSAGES and TREATMENT REGIMES?

III. Examples

Dr. Lentz - please insert examples.

described herein will be obvious to those skilled in the art. Such modifications and variations are intended to come within the scope of the appended claims.

11

I claim:

1. A method for inducing an immune response against transformed, infected or diseased tissue comprising:
removing components present in the blood having a molecular weight of 120,000 daltons or less, until the transformed, infected, or diseased tissue is reduced in amount.
2. The method of claim 1 wherein the tissue is a solid tumor.
3. The method of claim 1 wherein the components are removed from one blood volume.
4. The method of claim 1 wherein the components are removed in multiple treatments.
5. The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
6. The method of claim 1 further comprising selectively removing soluble TNF-alpha receptor molecules.
7. A system for inducing an immune response against transformed, infected or diseased tissue comprising:
a device for removing components present in the blood having a molecular weight of 120,000 daltons or less, and
an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
8. The system of claim 7 wherein the agent is an anti-angiogenic compound.
9. The system of claim 7 wherein the agent is a procoagulant compound.
10. The system of claim 7 wherein the agent is a cytokine.
11. The system of claim 10 wherein the cytokine is selected from the group consisting of...

OCT. 4. 2004 8:23PM

PABST PATENT GROUP

NO. 1732

P. 47

04/20/1998 13:08

16158340004

LENTZAPHERESISCENTER

PAGE 02

RightFAX NT

4/P 20

PAGE 17/20 RightFAX

12

12. The system of claim 7 wherein the agent is a chemotherapeutic agent.

13. The system of claim 12 wherein the agent is selected from the group consisting of alkylating agents, doxorubicin, carboplatinum, cisplatinum, and taxol.

14. The system of claim 7 wherein the device includes means for administering radiation to the tissue.

6. The method of claim 1 further comprising selectively removing soluble TNF-alpha receptor molecules.

21-2-2.

517066

170031





FIG. 2



May 2, 1998

Patrea L Pabst
Arnall Golden & Gregory, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450

Re: LEN 101 "*Method and Compositions for Treatment of Cancers*"

Dear Mrs. Pabst:

Thank you for your draft of the above titled patent application. As per your letter of April 30, 1998, I will attempt to respond herein to your request for additional information as described on pages 8&11 of the application.

Page 8, para beginning line 16 might read: "This procedure has been demonstrated to cause a significant response (greater than 50% reduction in size of tumors) in a variety of solid tumors in approximately 50% of patients who have failed all other treatment modalities. In metastatic melanoma clinical trials, a tumor specific inflammatory response provoked by ultrapheresis has been documented in approximately 75% of patients. This inflammation is characterized by redness, swelling, warmth, and tenderness and is confined to tumors only. There has been no associated injury to non-cancerous tissue. This tumor specific inflammatory response has led to a 50% or greater reduction in the size of tumors in 50% of patients studied so far. Clinical trials have also demonstrated a 44% major reduction of tumor metastases in human breast cancer, and prostate cancer. Insufficient clinical data exists to claim response rates in other tumor types but tumor specific inflammation has been observed in patients with metastatic colon cancer, ovarian cancer, lung cancer, head and neck cancer, cervical and endometrial cancers. In some cases this inflammation has been followed by significant tumor regressions in each tumor type. The significance of response in such diverse tumor types, strongly suggests that ultrapheresis modifies the patients response to the tumor in favor of successful immunologic control of the tumor.

Page 11 "Examples"

Mrs J.R. is a 44 year old lady who had metastatic breast cancer that had failed radiation therapy and the drugs; cytoxan, adriamycin, 5-FU, taxol, cis-platin, navalbine, tamoxofin and arimedex. Tumor at the time of ultrapheresis was documented in lungs, bone and skin of the entire left anterior and lateral chest. She was treated with 15 ultrapheresis procedures over a three week period. She experienced marked inflammation in the tumors in her skin, increased pain from the tumors in her bones, and swelling of the tumors in her lungs. She then received the drug thalidomide 200mg at night. The redness and swelling in her skin improved within 2 days and her breathing returned to normal within one week. Two weeks after completing treatment,

Len

all tumor in her skin had resolved clinically, her bone pain resolved and the tumors in her lungs resolved on repeat CAT scan. One week latter she returned to work as a school counselor. She is to all testing disease free two months after treatment and is being monitored closely on thalidomide at the same dose.

Mr. P.G. is a 54 year old engineer with metastatic melanoma with metastases to lung and to lymph nodes in the mediastinum. He received 24 ultrapheresis procedures resulting in a 25% reduction of tumors. He was subsequently treated with an additional 12 procedures resulting in minor tumor reduction despite evidence of tumor inflammation. The tumors regrew within one month. He was again retreated with ultrapheresis again resulting in inflammation and some minor regression but then received thalidomide at the time of tumor inflammation. Two months latter repeat CAT scan showed complete disappearance of tumors in the lung and mediastinum. He is being followed closely and shows no evidence of disease 6 months after completing treatment and has no medical complaints.

Mrs. J.K. is a 43 year old lady with metastatic leiomyosarcoma with six (6) lung metastases all of which developed within one month of surgery on both lungs to remove tumors. These tumors had also failed methotrexate, adriamycin, ifosphomide, and dactinomycin. She received 24 ultrapheresis procedures with no side effects. One month later CAT scan revealed only four (4) tumors and these were reduced in size by 50%.

Dr. R.S. is a 59 year old gentleman with metastatic adenocarcinoma of the left upper lung with metastases to liver, brain and bones. His tumors had failed to respond to taxol, cis-platin and etoposide. His brain tumors had responded to radiation therapy. He received 15 ultrapheresis procedures. Each procedure caused increased pain in tumors of his spine, pelvis, right hip and left shoulder. Follow up scans after ultrapheresis treatment revealed resolution of tumors in pelvis, spine, hip, and ribs. There was a 50% reduction in the primary tumor in the lung and liver. Thalidomide was then started at 200mg each night. One month latter the scans revealed further reduction in the tumors in lung and liver. The patient's pains have all resolved, he is asymptomatic.

I hope this information is helpful. If you need any additional information please call or we can use email. My address is rlentz@bellsouth.net. Thank you again for your good work, I am

Sincerely yours,

M. Rigdon Lentz M.D.